| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TSLP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于TSLP抗体的代表性文献，按研究重点分类列举：
---
**1. 抗TSLP抗体在哮喘的临床试验**
文献名称：*Tezepelumab in Adults with Uncontrolled Asthma*
作者：Corren J, et al.
摘要：报道抗TSLP单抗Tezepelumab治疗中重度哮喘的III期临床试验(NAVIGATOR研究)，证实其可显著降低哮喘急性发作率并改善肺功能，且安全性良好，支持TSLP作为哮喘治疗新靶点。
---
**2. TSLP在过敏性疾病中的机制研究**
文献名称：*Thymic stromal lymphopoietin promotes asthmatic airway inflammation via epithelial-immune cell interactions*
作者：Gauvreau GM, et al.
摘要：通过阻断TSLP抗体(如Tezepelumab)的临床前及早期临床试验，阐明TSLP通过激活上皮细胞与树突状细胞、Th2细胞的级联反应驱动哮喘炎症，抗体治疗可抑制多种炎症通路。
---
**3. 抗TSLP抗体在特应性皮炎中的应用**
文献名称：*Anti-TSLP Therapy with Tezepelumab in Atopic Dermatitis: A Phase IIa Study*
作者：Simpson EL, et al.
摘要：初步II期试验显示，Tezepelumab可显著改善中重度特应性皮炎患者的皮损和瘙痒症状，提示TSLP在皮肤屏障破坏及Th2型炎症中的核心作用。
---
**补充说明**：
- **TSLP抗体药物进展**：Tezepelumab(商品名Tezspire)是首个靶向TSLP的单抗，2021年获FDA批准用于严重哮喘，目前正拓展至慢性鼻窦炎、食物过敏等适应症。
- **研究趋势**：近年研究聚焦于TSLP在多种Th2相关疾病中的上游调控作用，以及其抗体相较于传统生物制剂(如抗IgE/IL-5)的广谱疗效优势。
如需更早期基础研究或特定疾病文献，可进一步补充方向。
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine critical in initiating and amplifying type 2 (Th2) immune responses. It plays a central role in allergic inflammation by activating dendritic cells, mast cells, and T-cells, driving the production of pro-inflammatory cytokines like IL-4. IL-5. and IL-13. Overexpression of TSLP is implicated in chronic allergic diseases, including asthma, atopic dermatitis, and chronic rhinosinusitis, making it a compelling therapeutic target.
TSLP-targeting monoclonal antibodies (e.g., tezepelumab) are biologics designed to neutralize TSLP or block its receptor interaction. By inhibiting TSLP signaling, these antibodies disrupt the inflammatory cascade at an early stage, potentially offering broader efficacy across multiple Th2-driven pathways compared to allergen-specific therapies. Clinical trials in severe asthma have demonstrated reduced exacerbations, improved lung function, and lowered eosinophil levels, even in patients with low baseline eosinophils. This highlights TSLP's role as a "master regulator" upstream of other cytokines like IL-5 or IgE.
Beyond asthma, TSLP antibodies are being explored for conditions like chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, and food allergies. Their mechanism addresses both allergic and non-allergic inflammation, positioning them as versatile agents in immune modulation. However, long-term safety and cost-effectiveness in real-world populations require further evaluation. Overall, TSLP inhibition represents a paradigm shift in treating Th2-high and mixed-endotype inflammatory diseases.
×
